Skip to content

    Piramal Pharma

    PPLPHARMA
    Healthcare·29 Apr 2026
    Management Summary

    Piramal Pharma navigated a transitional FY26, experiencing a year-on-year decline in reported revenues and EBITDA due to external headwinds and inventory de-stocking, alongside a significant intangible write-down. However, the underlying business showed modest growth, driven by strong H2 CDMO order inflows, the Kenalog acquisition, and robust consumer healthcare performance. The company anticipates a return to healthy early-to-mid-teen revenue growth in FY27, with EBITDA and PAT growing faster, despite an elevated debt-to-EBITDA ratio and projected continued quarterly volatility in CDMO.

    Highlights

    5
    • Underlying business performance (adjusted for de-stocking) showed modest growth in revenues and EBITDA in FY26.

    • Strong pickup in RFPs and order inflows for the CDMO business in H2 FY26, particularly for overseas sites with superior gross margins.

    • Consumer Healthcare business demonstrated strong growth, with Power Brands growing 24% for the full year and e-commerce growing 48%.

    • Successful completion of the Kenalog acquisition, expected to contribute revenue from Q2 FY27.

    • Maintained strong quality and regulatory compliance with Zero OAI in 3 US FDA inspections and improved ESG ratings.

    Concerns

    4
    • FY26 saw a year-on-year decline in reported revenues and EBITDA due to macroeconomic uncertainties, subdued biopharma funding, inventory de-stocking, and intensified competition.

    • An intangible asset write-down of INR 176 crores was recorded in Q4 FY26 due to changed market conditions and unmet return ratios for certain development projects.

    • Net debt-to-EBITDA remained elevated at 3.6 at FY26 end and is expected to stay in this range for FY27 due to ongoing capex.

    • Quarterly performance, especially for the CDMO segment, is expected to remain volatile and H2-weighted in FY27.

    Key financials

    Single quarter

    05 metrics
    1. 01Intangible Write-down₹176 Cr
    2. 02Net Debt-to-EBITDA3.6 x
    3. 03Net Promoter Score60 score
    4. 04ESG Score (SES)68.5 score
    5. 05ESG Score (NSE)64 score

    Segment breakdown

    CDMO
    ₹1,708 Cr Revenue₹4,915 Cr Revenue (Full Year)47% Revenue from Innovation-related work96 Mn Revenue from On-patent commercial manufacturing
    Consumer Healthcare
    17% Revenue Growth (Q4)17% Revenue Growth (Full Year)26% Power Brands Growth (Q4)24% Power Brands Growth (Full Year)48% E-commerce Growth (Full Year)30% E-commerce Share of PCH Sales
    Complex Hospital Generics
    47% US Inhalation Anesthesia Market Share (March 2024)
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹120 million

    Debt

    3.6x EBITDA

    M&A

    Kenalog (from BMS)

    acquisition · closed

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue Growth
    Revenue Growth
    early-to-mid-teen
    High
    Profitability
    EBITDA and PAT Growth
    growing faster than revenue
    High
    Revenue Phasing
    Revenue Weighting
    H2 weighted
    High
    Growth Momentum
    Growth Momentum
    build progressively from Q2 onwards
    High
    Capex
    Capex
    INR 120-135 million
    High
    Debt
    Net Debt-to-EBITDA
    ~3.6
    High
    Debt
    Net Debt-to-EBITDA
    ~1
    Low
    Tax Rate
    Consolidated Tax Rate
    24-25%
    Medium

    Kenalog acquisition revenue contribution

    Q2 FY27
    Currentexpected to commence from Q2 FY27
    TargetQuantified revenue contribution

    Why it matters

    This is a new product acquisition expected to drive growth and is specifically mentioned to start contributing in Q2.

    the completion of the Kenalog acquisition at the start of the year; steady ramping up of our sevoflurane supply to ex-US markets from Digwal.

    How to verify

    key_financials.segment_breakdown[name='Complex Hospital Generics'].metrics[label='Revenue']

    Risks & concerns

    6
    RiskSeverity

    Macroeconomic uncertainties and subdued biopharma funding

    Impacted FY26 revenues and EBITDA, though funding rebounded in H2.Management acknowledged

    medium

    Inventory de-stocking in key on-patent commercial products

    Led to year-on-year decline in revenues; no orders anticipated in near term for specific product.Management acknowledged

    high

    Intensified competition in inhalation anesthesia (non-US markets)

    Impacted performance in rest-of-world markets, being addressed with lower-cost supplies and regulatory approvals.Management acknowledged

    medium

    Middle East crisis impact on costs (raw materials, freight, insurance)

    Expect some cost escalations; situation fluid, exploring mitigation and passing on costs where possible on a case-by-case basis.Analyst acknowledged

    medium

    Volatility in quarterly performance, especially CDMO

    Inherent in business nature, CDMO (60% of revenue) is significantly skewed to H2/Q4, leading to lumpy quarters, expected to continue in FY27.Analyst acknowledged

    medium

    Uncertainty regarding tariffs and trade agreements (US-India FTA)

    While tariffs are net positive for US/UK sites, India's situation depends on negotiations; too early to comment on passing on costs if agreements are not signed.Analyst acknowledged

    medium

    Q&A highlights

    8

    “at the moment, we do not anticipate any orders in the near term from that customer. And if and when that changes, you'll see that in our forward-looking performance.”

    Clarifies that the significant revenue impact from this product is expected to continue in the near term, impacting FY27 outlook.

    asked by Brajesh Nirala

    3 min read6 chapters

    Detailed Narrative

    01

    Q4 FY26 Performance Overview and FY27 Outlook

    FY26 was a transitional year for Piramal Pharma, marked by macroeconomic headwinds, subdued biopharma funding in H1, and inventory de-stocking, leading to a year-on-year decline in reported revenues and EBITDA. However, when adjusted for de-stocking, the underlying business showed modest growth. The company exited the year on a stronger note, anticipating a return to healthy early-to-mid-teen revenue growth in FY27, with EBITDA and PAT growing faster. Revenue is expected to be H2 weighted in FY27, with growth momentum building progressively from Q2 onwards.

    02

    CDMO Business Dynamics and Growth Drivers

    The CDMO segment reported revenues of INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year. While H1 was impacted by slower RFPs, H2 saw a significant rebound in biopharma funding, leading to accelerated RFP activity and order inflows, particularly for overseas sites with superior gross margins. The company's win rate increased last year, attributed to its asset combination, strengthened business development, and high customer satisfaction, reflected in a Net Promoter Score of 60. Innovation-related work contributed 47% of FY26 CDMO revenues, with 96 million USD from on-patent commercial manufacturing.

    03

    Strategic Investments and Capacity Expansion

    Piramal Pharma is investing $90 million to expand sterile injectables and payload linker capabilities at its Lexington and Riverview sites. The Riverview expansion is already completed, while the larger Lexington phase is progressing as planned and is targeting completion by the end of calendar year 2027. These investments, alongside an expanded CDMO commercial team, aim to capitalize on high demand for differentiated capabilities like ADCs and HPAPI, and to leverage the onshoring trend, which is seen as a significant tailwind.

    04

    Complex Hospital Generics (CHG) and Consumer Healthcare (CHC) Performance

    The CHG business strengthened its US market leadership in inhalation anesthesia, with market share increasing to 47% by March 2024. The acquisition of Kenalog from BMS was completed and is expected to contribute revenue from Q2 FY27, bolstering the differentiated products portfolio. The CHC business demonstrated strong and consistent growth, with 17% revenue growth in Q4 FY26 and for the full year. This growth was driven by Power Brands, which grew 24% for the full year, and the e-commerce channel, which saw 48% growth and now accounts for approximately 30% of total PCH sales.

    05

    Capital Allocation, Debt Management, and Intangible Write-down

    The company reported a net debt-to-EBITDA ratio of 3.6 at the end of FY26, which is expected to remain in a similar range for FY27 due to ongoing capex. The FY27 capex is projected to be INR 120-135 million, primarily for the Lexington expansion. A one-time📎 intangible asset write-down of INR 176 crores was recorded in Q4 FY26. This impairment resulted from a strategic decision to cut further investments in certain development projects where market conditions changed and financial outcomes did not meet return ratios.

    06

    Regulatory Compliance and ESG Initiatives

    Piramal Pharma maintained a strong quality and regulatory track record, successfully completing 38 regulatory inspections, including three US FDA inspections, without any official action indicated (OAI). The company also underwent 209 customer audits during the year, reflecting heightened customer engagement. Sustainability efforts led to improved ESG ratings, with a score of 68.5 from SES ESG Research and 64 from NSE Sustainability Ratings, demonstrating commitment to decarbonization, waste management, and supply chain practices.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.